After the two compounds STU and ANP were further screened by predicting the absorption, distribution, metabolism, excretion and toxicity (ADMET) properties of all compounds using admetSAR , only STU (staurosporine) was found to be acceptable according to Lipinski’s rule of five  (Table S1). The absorption factors for STU resulted in high probabilities (97.3%) for human intestinal absorption, but moderate probabilities for blood brain barrier and CaCo-2 permeability. Under the metabolism profile, STU was found to be a substrate only for cytochrome P450 (CYP450) 3A4, a non-inhibitor for all different forms of CYP450, thus having high CYP inhibitory promiscuity. Under the toxicity profile, STU demonstrated the absence of mutagenic toxicity (a.k.a. AMES toxicity) and carcinogenic effects and also was found to be not toxic for fish and honey bee. Collectively, these data suggest that STU represents a safe and orally-absorbed drug candidate (Figure 7A), whereas the other compounds were ruled out for reasons, such as toxicity for fish (BK3 and CRK), AMES toxicity (DTQ), carcinogenicity (MRD) and violations of Lipinski’s rule (hydrogen bond acceptors, hydrogen bond donors and molecular weight for ANP) (Table S1).